Monday November 29, 6:00 am Eastern Time
Company Press Release
SOURCE: Sequenom, Inc.
Sequenom Announces Initial Public Offering of
Common Stock
SAN DIEGO, Nov. 29 /PRNewswire/ -- Sequenom, Inc. announced today that it has filed
a registration statement with the Securities and Exchange Commission for a public offering of
common stock lead managed by Warburg Dillon Read LLC. Robertson Stephens and SG
Cowen will also manage the offering. The underwriters will be granted a 30-day over-allotment option to purchase additional
shares of common stock from the company.
The company intends to use the proceeds of the offering primarily for general corporate purposes, including hiring of additional
sales and customer support personnel, expansion of its facilities, continued development and manufacturing of existing products,
research and development of additional products, patent prosecution expenses, working capital and potential acquisitions of
products, technologies or companies, and repayment of long-term debt and accrued interest of approximately $4.2 million.
Sequenom is a pioneer in the new field of industrial genomics, the large-scale commercial use of the knowledge of DNA
variations, or SNPs, for improving health, agriculture and livestock. The company's MassArray system combines proprietary
enzymology and bioinformatics in a miniaturized chip-based format with the proven technology of mass spectrometry. The
result is a highly accurate, cost-effective and scalable technology capable of high- throughput SNP analysis.
The Company is engaged in beta site testing with the U.S. Department of Agriculture, National Institutes of Health, National
Cancer Institute and Genzyme Corporation in the U.S. and University of Munster and GLE Medicon in Germany.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet
become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration
statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall
there be any sale of these securities in any State in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such State.
SOURCE: Sequenom, Inc. |
